DR MICHAELS® (SORATINEX®) PRODUCT FOR THE TOPICAL TREATMENT OF PSORIASIS: A HUNGARIAN/ CZECH AND SLOVAK STUDY

J. HERCOGOVÁ1,2, M. FIORANELLI1, S. GIANFALDONI4, A.A. CHOKOEVÁ1,6, G. TCHERNEV7, U. WOLLINA3, M TIRANT8, F. NOVOTNY10, M.G. ROCCIA11, G.K. MAXIMOVIČ12, K. FRANÇA13,14 and T. LOTTI15

12nd Medical Faculty, Charles University, Bulovka Hospital, 3Institute of Clinical and Experimental Medicine, Prague, Czech Republic; 1Department of Nuclear Physics, Sub-nuclear and Radiation, G. Marconi University, Rome, Italy; 4Dermatological Department University of Pisa, Pisa, Italy; 1,6"Onkoderma"-Policlinic for dermatology and dermato logic surgery, Sofia, Bulgaria; 4Department of Dermatology and Venereology, Medical University of Plovdiv, Medical faculty, Plovdiv, Bulgaria; 5Medical Institute of Ministry of Interior (MVR), Department of Dermatology, Venereology and Dermatologic Surgery, Sofia, Bulgaria; 4Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany; 6Psoriasis & Skin Clinic, Melbourne, Australia; 10PRO SANUM Ltd., Sanatorium of Prof. Novotný, Štěpánská Prague 1, Czech Republic; 11University B.Is. Group of Institutions, Punjab Technical University, Punjab, India; 12Department "Medical Information and Non-interventional studies", Bulgarian Drug Agency, Sofia, Bulgaria; 13Department of Dermatology & Cutaneous Surgery, Department of Psychiatry & Behavioral Sciences, Institute for Bioethics & Health Policy, University of Miami, Miller School of Medicine, Miami, FL, USA; 14Centro Studi per la Ricerca Multidisciplinare e Rigenerativa, Università Degli Studi "G. Marconi", Rome, Italy; 15Chair of Dermatology, University of Rome "G. Marconi" Rome, Italy

Psoriasis is a chronic inflammatory T cell-mediated skin disease, affecting about 2% of Hungarian population. Genetic predisposition as well as environmental triggering factors, and innate immune processes play a role in its etiology. Treatment of psoriasis during the initial stages and first years of disease tend to be conservative and frequently based on topical agents. The aim of this study was to investigate and to describe the efficacy and safety of Dr Michaels® (Soratnex®) skin-care products for the topical treatment of stable chronic plaque psoriasis in a Hungarian population. Two-hundred-and-eight-six (120 female/166 male) patients, aged 10-80 years old (mean age 43 years) with mild to moderate plaque psoriasis had participated in the study. The products, including cleansing gel containing a coal tar solution, herbal oils and emulsifiers, were used twice daily and in the same manner for all the skin lesions. The study period was eight weeks. Assessment, using the Psoriasis Activity Severity Index (PASI) scores and photographic analysis, was done 2 weeks before treatment, at time 0, and after 2, 4, 6 and 8 weeks. Patient’s improvement was determined by the percentage reduction of the PASI scores. Side effects and tolerability were also evaluated. After 8 weeks treatment course, 46 patients had a moderate improvement, with the regression of 25-50% of skin lesions; 77 patients showed a good improvement, with the resolution of 51-75% of lesions. Another 115 patients had an outstanding improvement, with the regression of 76-98.9% of lesions. Only 13 patients did not achieve an improvement of psoriasis. Fifteen patients experienced folliculitis, which resolved after cessation of treatment. Seven patients worsened and discontinued treatment. Thirteen patients dropped out because of non-compliance. Our investigation demonstrates that Dr Michaels® (Soratnex®) products, an Australian treatment, can be used successfully in the treatment of stable chronic plaque psoriasis.